Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - protonix i.v. is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (gerd) and a history of erosive esophagitis (ee). safety and efficacy of protonix i.v. as a treatment of patients with gerd and a history of ee for more than 10 days have not been demonstrated. protonix i.v. is indicated for the treatment of pathological hypersecretory conditions including zollinger-ellison (ze) syndrome in adults. risk summary available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pantoprazole. in animal reproduction studies, no evidence of adverse development outcomes was observed with pantoprazole. reproduction studies have been performed in rats at intravenous doses up to 20 mg/kg/day (4 times the recommended human dose) and rabbits at intravenous doses up to 15 mg/kg/day (6 times the recommended human dose) with administration of pantoprazole during organogenesis in pregnan

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

wyeth pharmaceuticals company - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - pain reliever/fever reducer - temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis - headache - toothache - backache - menstrual cramps - the common cold - muscular aches - minor pain of arthritis - temporarily reduces fever

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w), piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx) -       zosyn is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . zosyn is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin and tazobactam-susceptible acinetobacter baumannii , haemophilus influenzae , klebsiella pneumoniae , and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2)] . zosyn is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesse

Israel - engleză - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - solution (oral) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Panama - engleză - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

wyeth pharmaceuticals, inc. - factor viii recombinante (moroctocog alfa) - factor viii recombinante (moroctocog alfa)....250 ui / cloruro de sodio al 0.9%....4 ml

Panama - engleză - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

wyeth pharmaceuticals, inc. - factor viii recombinante (moroctocog alfa) - factor viii recombinante (moroctocog alfa)....500 ui / cloruro de sodio al 0.9%....4 ml

Panama - engleză - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

wyeth pharmaceuticals llc - moroctocog alfa (af-cc) - moroctocog alfa (af-cc)....1000 ui / cloruro de sodio....37.8 mg

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pediatric indication and usage information in pediatric patients ages 5 years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals inc.’s pantoprazole sodium delayed-release tablets. however, due to wyeth pharmaceuticals inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartbu

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium delayed-release tablets usp are indicated for: pantoprazole sodium delayed-release tablets usp are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets usp may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals inc.’s pantoprazole sodium delayed-release tablets. however, due to wyeth pharmaceuticals inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. pantoprazole sodium delayed-release tablets usp are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime an

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - pristiq, a selective serotonin and norepinephrine reuptake inhibitor (snri), is indicated for the treatment of major depressive disorder (mdd) [see clinical studies ( 14 ) and dosage and administration ( 2.1 ) ]. the efficacy of pristiq has been established in four 8-week, placebo-controlled studies of outpatients who met dsm-iv criteria for major depressive disorder. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in th